目的 探討脈血康膠囊聯(lián)合注射用尿激酶治療下肢深靜脈血栓的臨床療效。方法 選取2019年9月—2021年7月在平頂山市第二人民醫(yī)院就診的91例下肢深靜脈血栓患者，根據(jù)隨機(jī)數(shù)字表法將所有患者分為對(duì)照組（45例）和治療組（46例）。對(duì)照組患者于患肢足背靜脈微量泵入注射用尿激酶，30萬單位加入生理鹽水500 mL中充分稀釋，1次/d。治療組在對(duì)照組基礎(chǔ)上口服脈血康膠囊，1.0 g/次，3次/d。兩組患者連續(xù)治療2周。觀察兩組臨床療效，比較兩組患者治療前后周徑差、疼痛程度、血流參數(shù)、血清炎癥因子水平。結(jié)果 治療后，治療組的總有效率（89.13%）明顯高于對(duì)照組的總有效率（71.11%）（P<0.05）。治療后，兩組周徑差、視覺模擬評(píng)分法（VAS）顯著降低（P<0.05），治療組周徑差、VAS評(píng)分較對(duì)照組降低更明顯（P<0.05）。治療后，兩組的凝血時(shí)間（K值）、反應(yīng)時(shí)間（R值）明顯升高，最大振幅（MA）顯著降低（P<0.05）；治療組的K值、R值高于對(duì)照組，MA低于對(duì)照組（P<0.05）。治療后，兩組的白細(xì)胞介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）、白細(xì)胞介素-8（IL-8）水平顯著降低（P<0.05）；治療組的IL-6、TNF-α、IL-8水平比對(duì)照組低（P<0.05）。結(jié)論 脈血康膠囊聯(lián)合注射用尿激酶治療下肢深靜脈血栓的臨床療效確切，能有效減輕水腫和疼痛程度，改善患肢的血液循環(huán)，調(diào)節(jié)血清IL-6、TNF-α、IL-8水平，安全性較好。

Objective To investigate the clinical efficacy of Maixuekang Capsules combined with Urokinase for injection in treatment of lower extremity deep venous thrombosis. Methods Patients (91 cases) with lower extremity deep venous thrombosis in Pingdingshan the Second People's Hospital from September 2019 to July 2021 were randomly divided into the control group (45 cases) and the treatment group (46 cases). Patients in the control group were micro-pumped Urokinase for injection into the dorsal vein of the affected limb, 300 000 units fully diluted in 500 mL normal saline, once daily. Patients in the treatment group were po administered with Maixuekang Capsules on the basis of the control group, 1.0 g/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and peripheral diameter difference, pain degree, blood flow parameters, the levels of inflammatory factors in two groups were compared. Results After treatment, the total effective rate of the treatment group (89.13%) was significantly higher than that of the control group (71.11%) (P < 0.05). After treatment, the peripheral diameter difference and VAS score of two groups were significantly decreased (P < 0.05), and after treatment, the peripheral diameter difference and VAS score of the treatment group were significantly lower than those of the control group (P < 0.05). After treatment, the K value and R value in two groups were significantly increased, but the MA in two groups were significantly decreased (P < 0.05). After treatment, the K value and R value of the treatment group were higher than those of the control group, but the MA of the treatment group was lower than that of the control group (P < 0.05). After treatment, the levels of IL-6, TNF-α, and IL-8 in two groups were significantly decreased (P < 0.05). The levels of IL-6, TNF-α, and IL-8 in the treatment group were lower than those in the control group (P < 0.05). Conclusion Maixuekang Capsules combined with Urokinase for injection is effective in treatment of lower extremity deep venous thrombosis, which can effectively reduce the degree of edema and pain, improve the blood circulation of affected limbs, and regulate the serum levels of IL-6, TNF-α, and IL-8, with good safety.

R973

河南省社科聯(lián)、河南省經(jīng)團(tuán)聯(lián)調(diào)研課題（SKL-2018-497）